Brookings Roundtable on Active Medical Product Surveillance: Overview of FDA’s Sentinel Initiative
Past Event
Brookings Roundtable on Active Medical Product Surveillance: Overview of FDA’s Sentinel Initiative
It has been three years since FDA launched the Sentinel Initiative and, since then, FDA has made significant progress. On September 7, the Engelberg Center hosted the first of the three-part Sentinel Initiative 101 Webinar Series, “Overview of FDA’s Sentinel Initiative” to review ongoing activities and accomplishments. The roundtable featured a presentation from Dr. Judy Racoosin, Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
Dr. Racoosin’s presentation provided a high-level review of the Sentinel Initiative’s scope and achievements including:
- FDA’s 3-year vision for the Sentinel Initiative
- A brief overview of the role of the Mini-Sentinel pilot, the Observational Medical Outcomes Partnership, the Federal Partners Collaboration, and the Brookings Institution cooperative agreement
- Next steps for the Sentinel Initiative
Subsequent webinars in this series will provide a more in-depth overview of these pilot activities.
Agenda
Welcome and Introduction
Mark B. McClellan
Former Brookings Expert
Director, Margolis Center for Health Policy - Duke University
Overview of Sentinel Initiative
Judy Racoosin
Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research
More Information
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.
